CVD Clinical Trial
Official title:
Phase 4 of Atorvastatin for Preventing Occlusion and Restenosis After Intracranial Artery Stenting
Severe intracranial atherosclerosis with concomitant stenosis is responsible for approximately 10% of all strokes. Retrospective studies have indicated that up to 50% of patients with a recently symptomatic intracranial stenosis experience recurrent ischemic events. Due to the high stroke risk, patients with high grade 70% symptomatic intracranial stenosis represent the main target group for endovascular treatment. Atorvastatin is widely used in the treatment of hyperlipidemia, especially after acute myocardial infarction. High-dose atorvastatin has been known to stop the progression of atherosclerosis and to decrease the levels of inflammatory markers. Several recent clinical trials have proved atorvastatin can reduce restenosis after stent implantation in coronary artery. But the feasibility of atorvastatin in preventing restenosis in patients with intracranial stenting has not been evaluated.The purpose of this prospective, randomized, single-blinded trial is to evaluate the effect of atorvastatin 80 mg daily in preventing restenosis and related vascular events in patients with intracranial stent implantation.
Severe intracranial atherosclerosis with concomitant stenosis is responsible for
approximately 10% of all strokes. In Asian populations intracranial stenoses are even the
most commonly found vascular lesions. Retrospective studies indicated that up to 50%
patients with recently symptomatic intracranial stenosis experienced recurrent ischemic
events. The risk of recurrent stroke increases with the aggravation of intracranial artery
stenosis. In Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial, 14% and 23% of
the patients with TIA or stroke attributable to high-grade intracranial stenosis had further
ipsilateral ischemic stroke over the next year despite best medical treatments. If
percentage of intracranial stenosis exceeded 70%, the stroke risk went up to 20% in the
first year. These results spurred the enthusiasm for endovascular approaches, including
percutaneous transluminal balloon angioplasty (PTA) and stenting to treat this potentially
harmful disease. Due to the high stroke risk, patients with high-grade ≥70% symptomatic
intracranial stenosis represent the main target group for endovascular treatment.
Endovascular management of intracranial arthrosclerosis is, however, associated with an
appreciable number of potential complications, including local thrombosis, thromboembolism
and, especially, restenosis and in-stent occlusion. To date, the reported 1-year restenosis
rates after intracranial stenting in case series and small trials have varied widely,
ranging from less than 10% in some to more than 50% in others. According to a recent review,
the overall 1-year restenosis rate of intracranial stenting was 25%, and the in-stent
occlusion rate was nearly 10%. These relatively high rates of restenosis and re-occlusion
after procedure have raised the question about whether stenting improves the natural course
of intracranial atherosclerosis.
Compared with the relatively good durability of angioplasty and stenting procedures within
the extracranial carotid artery, the high incidence of restenoses appears to be a major
drawback of intracranial stenting. Recent studies suggested that especially younger patients
treated with self-expandable stents within the anterior circulation have a higher risk for
this complication. Considering about 33% of restenoses were symptomatic (TIA or stroke),
decreasing restenosis rates after intracranial stenting became the key issue for improving
the clinical feasibility of this treatment strategy.
Animal studies have indicated that statins can inhibit platelet aggregation and release of
platelet-derived mediators, reduce inflammatory responses of vascular wall, improve artery
endothelial function, all of which may contribute to decrease proliferative responses after
stent implantation. These profiles make statin optimal for preventing restenosis or
occlusion after intracranial stenting, but this strategy has not been tested by clinical
trials to date, although statin has been proved by several recent clinical trials to be
efficacious in preventing restenosis after stent implantation in coronary arteries.
The initial attempts to lower restenosis rates after coronary balloon angioplasty have
failed to demonstrate beneficial effects of statin therapy, although the FLuvastatin
Angioplasty REstenosis (FLARE) trial reported a reduction in mortality and myocardial
infarction in the fluvastatin treatment patients. Subsequent studies, however, did confirm
that statin therapy can decrease restenosis rates and the related ischemic events after
stent implantation in patients with coronary artery diseases. Unlike chronic vessel
shrinkage may account for ≥70% of recurrence rates after balloon angioplasty, restenosis
after coronary stent implantation is entirely due to neointimal proliferation. Experimental
studies have shown that statins are capable of inhibiting intimal proliferation after
arterial injury. Results from other studies suggested that statins interfere with
proliferative responses after coronary stent implantation in humans. Statin therapy was
associated not only with a significant reduction in late lumen loss, but also with a greater
net gain after coronary stent implantation. Thus, the discrepancy of the effects of statin
therapy on restenosis development after balloon angioplasty compared with coronary stent
implantation may be easily reconciled by the different mechanisms underlying the recurrence
of luminal narrowing.
Elevated LDL cholesterol levels increase platelet and red-cell aggregability, and thrombosis
is believed to have a decisive role in the process of restenosis and in-stent occlusion.
Lowering LDL cholesterol levels decreases rates of restenosis in the rat-carotid model,
whereas treatment with statin decreases the progression of disease in the rabbit-iliac model
independently of an effect on LDL cholesterol. In contrast, in the
overstretched-swine-coronary model, no relation between either LDL cholesterol or statin and
restenosis was observed. An attempt was made to resolve these conflicts with a prospective
clinical study in which 157 patients were treated with or without statin. The results
indicated that the rate of restenosis was 12 percent with and 44 percent without statin.
More than one study also identified the diagnosis of hypercholesterolemia at the time of
coronary stent implantation as a major independent predictor for reduced recurrence rates.
But a recent study indicated that statin therapy was associated with a comparable reduction
of restenosis rates in patients with average serum cholesterol levels at baseline, suggest
that the observed effects are not only due to reduced serum cholesterol levels, but also may
be related to the non-lipid anti-atherosclerotic properties of statins.
Since the efficacy of high dose statin in preventing restenosis after coronary artery
stenting has been confirmed by several clinical trials, it is reasonable to presume that
high-dose statin is also efficacious in preventing restenosis and in-stent occlusion after
intracranial stenting, because these two vasculatures share very similar anatomical
profiles. The present study is aimed to evaluate the preventive effects of atorvastatin 80
mg daily in decreasing restenosis in a consecutive series of patients undergoing
intracranial stent implantation at a single center. The hypotheses of this study is that
patients with atorvastatin therapy is associated with improved clinical outcome and reduced
restenosis rates 12 months after intracranial stent implantation than patients without
atorvastatin therapy.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02480504 -
Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity
|
N/A | |
Completed |
NCT02440893 -
Understanding the Effect of Metformin on Corus CAD (or ASGES)
|
||
Completed |
NCT01486030 -
Effect of Exercise Stress Testing on Peripheral Gene Expression Using Corus CAD (or ASGES) Diagnostic Test
|
||
Active, not recruiting |
NCT00038727 -
Diabetes Prevention Program Outcomes Study
|
Phase 3 | |
Completed |
NCT03967678 -
Omega (n)-3 PUFA Enriched Beef & Health Outcomes.
|
N/A | |
Completed |
NCT01251302 -
Utility of a Molecular Personalized Coronary Gene Expression Test (Corus CAD or ASGES) on Cardiology Practice Pattern
|
||
Not yet recruiting |
NCT05716659 -
EEG/MECG/EMG Evaluating the Severity of Aortic Stenosis, Heart Failure and Ischemic Stroke Through an Artificial Intelligenceassisted System.
|
||
Withdrawn |
NCT02158754 -
Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making
|
||
Completed |
NCT01077388 -
e-Care for Heart Wellness
|
Phase 3 | |
Completed |
NCT04384029 -
The Geneva Covid-19 CVD Study
|
||
Active, not recruiting |
NCT02382822 -
Copenhagen Co-morbidity in HIV Infection Study
|
||
Active, not recruiting |
NCT01825668 -
Effect of Plant Sterol Enriched Milk on Plasma Lipid Levels of Humans Breast-fed During Infancy
|
N/A | |
Completed |
NCT02223286 -
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making
|
N/A | |
Completed |
NCT00289237 -
Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease
|
N/A | |
Not yet recruiting |
NCT03658031 -
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
|
Phase 3 | |
Completed |
NCT03636529 -
Tart Cherry Juice and Markers of Inflammation, CVD, and Diabetes
|
N/A | |
Completed |
NCT00500708 -
Diagnostic Investigation of Sudden Cardiac Event Risk
|
N/A | |
Completed |
NCT00500617 -
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
|
||
Completed |
NCT00583297 -
Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial
|
N/A | |
Completed |
NCT02405754 -
Clinical Utility of an Age, Sex, and Gene Expression Score (ASGES or Corus CAD) in African American Patients.
|